About Ollin Bio

Ollin Bio develops novel bispecific antibody therapies for severe ophthalmic diseases like wet AMD and DME. Their lead candidate, OLN324, targets VEGF-A and Angiopoietin-2 to improve anatomic outcomes beyond current anti-VEGF treatments.

<problem> Patients with severe, vision-threatening ophthalmic diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) often experience progressive disease despite current anti-VEGF therapies, necessitating frequent intravitreal injections. Existing treatments can be insufficient, leading to suboptimal anatomic outcomes and continued vision loss. </problem> <solution> Ollin Bio is developing novel therapeutic candidates designed to improve outcomes for patients with severe, vision-threatening ophthalmic conditions. The company's pipeline focuses on advancing treatments that build upon validated biologies while balancing risk and innovation to achieve best-in-disease status. Ollin Bio's approach aims to address unmet needs by targeting a broader spectrum of disease mechanisms. Their lead candidate, OLN324, is a higher potency, small format bispecific antibody targeting both VEGF-A and Angiopoietin-2 (Ang2), which has demonstrated improved anatomic outcomes compared to anti-VEGF therapy alone in preclinical models. Another candidate, OLN102, is a first-in-class bispecific antibody targeting IGF-1R and TSHR, intended for conditions like thyroid eye disease. </solution> <features> - OLN324: A VEGF-A/Ang2 bispecific antibody designed for enhanced efficacy in wet AMD and DME. - OLN102: A first-in-class IGF-1R/TSHR bispecific antibody for indications including thyroid eye disease. - Pipeline development grounded in validated biological pathways with defined regulatory strategies. - Focus on delivering potential best-in-disease therapies through a combination of risk mitigation and innovation. - Preclinical and early clinical stage drug candidates targeting significant unmet needs in ophthalmology. </features> <target_audience> Ollin Bio's primary customers are patients suffering from severe, vision-threatening ophthalmic diseases and the healthcare providers who treat them, including ophthalmologists and retinal specialists. </target_audience> <revenue_model> Revenue generation is anticipated through the successful development, regulatory approval, and commercialization of its therapeutic candidates, likely via licensing agreements, partnerships, or direct sales of approved pharmaceuticals. </revenue_model>

What does Ollin Bio do?

Where is Ollin Bio located?

Ollin Bio is based in Austin, United States.

How much funding has Ollin Bio raised?

Ollin Bio has raised 100000000.

Location

Austin, United States

Funding

100000000

Employees

14 employees

Major Investors

ARCH Venture Partners, Monograph Capital

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Ollin Bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

ollin.bio 1K+

Crunchbase

Austin, United States

Funding

Estimated Funding

$100M+

Major Investors

ARCH Venture Partners, Monograph Capital

Team (10+)

No team information available.

Company Description

Problem

Patients with severe, vision-threatening ophthalmic diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) often experience progressive disease despite current anti-VEGF therapies, necessitating frequent intravitreal injections. Existing treatments can be insufficient, leading to suboptimal anatomic outcomes and continued vision loss.

Solution

Ollin Bio is developing novel therapeutic candidates designed to improve outcomes for patients with severe, vision-threatening ophthalmic conditions. The company's pipeline focuses on advancing treatments that build upon validated biologies while balancing risk and innovation to achieve best-in-disease status. Ollin Bio's approach aims to address unmet needs by targeting a broader spectrum of disease mechanisms. Their lead candidate, OLN324, is a higher potency, small format bispecific antibody targeting both VEGF-A and Angiopoietin-2 (Ang2), which has demonstrated improved anatomic outcomes compared to anti-VEGF therapy alone in preclinical models. Another candidate, OLN102, is a first-in-class bispecific antibody targeting IGF-1R and TSHR, intended for conditions like thyroid eye disease.

Features

OLN324: A VEGF-A/Ang2 bispecific antibody designed for enhanced efficacy in wet AMD and DME.

OLN102: A first-in-class IGF-1R/TSHR bispecific antibody for indications including thyroid eye disease.

Pipeline development grounded in validated biological pathways with defined regulatory strategies.

Focus on delivering potential best-in-disease therapies through a combination of risk mitigation and innovation.

Preclinical and early clinical stage drug candidates targeting significant unmet needs in ophthalmology.

Target Audience

Ollin Bio's primary customers are patients suffering from severe, vision-threatening ophthalmic diseases and the healthcare providers who treat them, including ophthalmologists and retinal specialists.

Revenue Model

Revenue generation is anticipated through the successful development, regulatory approval, and commercialization of its therapeutic candidates, likely via licensing agreements, partnerships, or direct sales of approved pharmaceuticals.